SeaStar Medical is trading at $2.09, up 8.74% versus the November 5 close, with no clear company-specific catalyst identified for the pre-market rise. - The November 4 company update scheduled third-quarter results for November 11; it was not a results announcement. - FDA confirmation that QUELIMMUNE’s post-approval study requirements were fulfilled was announced November 3, before this move. - Major indices are mixed; a broader-market cause is unclear.